Revisit key insights, watch expert discussions, and access presentation materials from Bayer's activities at WCLC 2026.
Bayer-sponsored symposium | From evidence to early adoption: A comprehensive approach to the management of HER2-mutant NSCLC
Drawing on clinical evidence and patient perspectives, Professor Tony Mok, Dr Soo Ryum (Stewart) Yang and Marcia Horn highlighted the following key messages:
- Profile. Profile. Profile - Biomarker testing is important at diagnosis and throughout the patient journey
- Test accurately and interpret carefully - Understanding different HER2 alterations is critical for clinical decision-making in NSCLC
- Activating HER2 mutations in NSCLC represent a distinct molecular subtype - Consider HER2 within the broader NSCLC biomarker landscape
- Historical outcomes with conventional therapies have been modest - Biomarker-driven management is increasingly important in HER2-mutant NSCLC
- Evidence continues to evolve - Emerging data are refining our understanding of HER2-mutant NSCLC and its management
2. Meet the Expert series: Clinical perspectives in HER2-mutant NSCLC
Bayer hosted a series of focused Meet the Expert discussions featuring international faculty sharing practical clinical perspectives across the patient journey in HER2-mutant NSCLC.
Recordings of all sessions, as well as the supporting slides, are available below.
Precision in practice: Identifying the HER2-mutant NSCLC patient with Dr. Helena Yu
In this session, Dr. Helena Yu explores the identification of patients with HER2-mutant NSCLC and highlights the following key takeaways:
- HER2-mutant NSCLC is a distinct molecular subtype - Comprehensive genomic testing is essential to identify activating HER2 mutations in NSCLC
- Timely identification of activating mutations improves treatment outcomes for patients with NSCLC with activating HER2 mutations - Molecular profiling should begin at diagnosis and be considered throughout the patient journey to support informed treatment decisions
- Molecular test results inform treatment decision making - Accurate interpretation of biomarker results enables clinicians to personalize the care of patients with NSCLC
Click here to access the presentation slides and session recording.
Decisions in practice: The role of sevabertinib in HER2-mutant NSCLC with Dr. Herbert Loong
In this session, Dr. Herbert Loong discusses the evolving treatment landscape and clinical considerations for the use of sevabertinib in HER2-mutant NSCLC, while emphasizing the following key takeaways:
- The treatment landscape for HER2-mutant NSCLC continues to evolve - Precision therapeutics are now available to improve outcomes for patients with NSCLC with activating HER2 mutations
- Sevabertinib is an oral, potent and reversible TKI that targets activating HER2 mutations - Sevabertinib demonstrated robust efficacy in pre-treated patients with HER2 TKD mutations
- Understanding the data for available treatment options is essential - Evidence-based decision-making is important for personalized care
Click here to access the presentation slides and session recording.
Confidence in practice: Practical management of patients receiving sevabertinib for HER2-mutant NSCLC with Dr. Xiuning Le
Gain practical insights into supporting patients receiving sevabertinib with Dr. Xiuning Le who outlines the following key take-home messages:
- Optimal treatment begins with proactive planning - Patient education, monitoring, and supportive care strategies for patients receiving sevabertinib should be applied
- Sevabertinib-associated diarrhea is common but manageable – Episodes of diarrhea were generally not sustained or recurrent, and were effectively managed with dose modifications and antidiarrheals
- Ongoing monitoring and early management can support tolerability, adherence, and long-term treatment success - TKI-associated diarrhea is currently being managed sufficiently in the clinic
Click here to access the presentation slides and session recording.
Thank you for exploring Bayer's WCLC 2026 HER2-mutant NSCLC content. We hope these expert perspectives and practical insights prove valuable in clinical practice.
These initiatives were developed and offered by Bayer. They were not part of the official program of the International Association for the Study of Lung Cancer.
MA-M_SEV.-KR-0015 | July 2026